Boston.com
Local Search Site Search
Home Delivery
  • Home
  • Today's Globe
  • News
  • Your Town
  • Business
  • Sports
  • Lifestyle
  • A&E
  • Things to do
  • Travel
  • Cars
  • Jobs
  • Real Estate
  • Technology
  • Healthcare
  • Markets
  • Personal finance
  • Columnists

30 most innovative people in Massachusetts

Biotech and Pharmaceutical 1. Henri Termeer Position: Chairman and CEO of Genzyme Corp. Termeer, who joined the company as president in 1983, built up Genzyme Corp., which makes medicines that treat rare genetic disorders and other diseases like Gaucher's disease. This year, the company was sold to French drug maker Sanofi-Aventis SA for $20 billion, a deal that Termeer helped to craft by creating a unique milestone payment mechanism, called a contingent value right, that will reward Genzyme investors if drugs in its pipeline succeed. >> Full profile
Illustration by Joel Kimmel
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • ...
  • 21
  • Next
Photo gallery

Globe 100 top firms

Globe 100 top firms
Top-ranked firms in Massachusetts in each industry.
2011 Boston Globe 100 - Ranking of Massachusetts businesses
  • No. 1 Clean Harbors shines  |  List Globe 100
  • Analysis Glamour out of style
  • Methodology How we calculate the numbers
  • Q&A Inside the minds of innovative CEOs
  • How CEOs de-stress  |  Video  |  Submit
  • Photos Products made in Massachusetts
  • Photos Globe 100 winners since 2000
  • All Globe 100 charts  |  Videos  |  Full coverage

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

  • E-mail
  • Facebook
  • Twitter
  • Digg
  • ShareThis
  • Prev
  • 4 of 21
  • Next
Biotech and Pharmaceutical

1. Henri Termeer

Position: Chairman and CEO of Genzyme Corp.

Termeer, who joined the company as president in 1983, built up Genzyme Corp., which makes medicines that treat rare genetic disorders and other diseases like Gaucher's disease. This year, the company was sold to French drug maker Sanofi-Aventis SA for $20 billion, a deal that Termeer helped to craft by creating a unique milestone payment mechanism, called a contingent value right, that will reward Genzyme investors if drugs in its pipeline succeed. >> Full profile

  • Home
  • |
  • Today's Globe
  • |
  • News
  • |
  • Business
  • |
  • Sports
  • |
  • Lifestyle
  • |
  • A&E
  • |
  • Things to Do
  • |
  • Travel
  • |
  • Cars
  • |
  • Jobs
  • |
  • Real Estate
  • |
  • Local Search
  • Contact Boston.com
  • |
  • Help
  • |
  • Advertise
  • |
  • Work here
  • |
  • Privacy Policy
  • |
  • Your Ad Choices
  • |
  • Terms of Service
  • |
  • |
  • Mobile
  • |
  • RSS feeds
  • |
  • Sitemap
  • Contact The Boston Globe
  • |
  • Subscribe
  • |
  • Manage your subscription
  • |
  • Advertise
  • |
  • Boston Globe Insiders
  • |
  • The Boston Globe Gallery
  • |
  • © NY Times Co.